Literature DB >> 21085622

COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.

Tanya B Dorff1, Cathy M Tangen, E David Crawford, Daniel P Petrylak, Celestia S Higano, Derek Raghavan, David I Quinn, Nicholas J Vogelzang, Ian M Thompson, Maha H A Hussain.   

Abstract

The major goals of the SWOG-GU committee in the area of advanced prostate cancer are to improve the survival and quality of life of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-naïve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.

Entities:  

Year:  2009        PMID： 21085622      PMCID： PMC2981166          DOI： 10.1177/1758834009343454

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  57 in total

1.  EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE.

Authors:  C Huggins
Journal:  Ann Surg       Date:  1942-06       Impact factor: 12.969

Review 2.  Androgen receptor signaling in androgen-refractory prostate cancer.

Authors:  M E Grossmann; H Huang; D J Tindall
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

3.  A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.

Authors:  K J Pienta; B G Redman; R Bandekar; M Strawderman; K Cease; P S Esper; H Naik; D C Smith
Journal:  Urology       Date:  1997-09       Impact factor: 2.649

4.  A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407).

Authors:  K J Pienta; E I Fisher; M A Eisenberger; G M Mills; J W Goodwin; J A Jones; S R Dakhil; E D Crawford; M H Hussain
Journal:  Prostate       Date:  2001-03-01       Impact factor: 4.104

5.  Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.

Authors:  P C Smith; E T Keller
Journal:  Prostate       Date:  2001-06-15       Impact factor: 4.104

6.  Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

Authors:  Maha Hussain; Catherine M Tangen; Primo N Lara; Ulka N Vaishampayan; Daniel P Petrylak; A Dimitrios Colevas; Wael A Sakr; E David Crawford
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

7.  Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

Authors:  D M Savarese; S Halabi; V Hars; W L Akerley; M E Taplin; P A Godley; A Hussain; E J Small; N J Vogelzang
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

8.  Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.

Authors:  P F Schellhammer; P Venner; G P Haas; E J Small; P T Nieh; D R Seabaugh; A L Patterson; E Klein; Z Wajsman; B Furr; Y Chen; G J Kolvenbag
Journal:  J Urol       Date:  1997-05       Impact factor: 7.450

9.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Authors:  M A Eisenberger; B A Blumenstein; E D Crawford; G Miller; D G McLeod; P J Loehrer; G Wilding; K Sears; D J Culkin; I M Thompson; A J Bueschen; B A Lowe
Journal:  N Engl J Med       Date:  1998-10-08       Impact factor: 91.245

10.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.